1. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020; 9(1): 221-36. [DOI:10.1080/22221751.2020.1719902]

2. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. The Lancet Neurology. 2020. [DOI:10.2139/ssrn.3589350]

3. Yuki N, Hartung H-P. Guillain-Barré syndrome. New England Journal of Medicine. 2012; 366(24): 2294-304. [DOI:10.1056/NEJMra1114525]

4. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proceedings of the National Academy of Sciences. 2004; 101(31): 11404-9. [DOI:10.1073/pnas.0402391101]

5. van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994; 45(3): 114-22.

6. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2016(10). [DOI:10.1002/14651858.CD001446.pub5]

7. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology. 2008; 7(10): 939-50. [DOI:10.1016/S1474-4422(08)70215-1]

8. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID‐19-associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & nerve. 2020; 62(4): 485-91. [DOI:10.1002/mus.27024]